immunomodulator

[키워드] 1:1 95% CI added Administered Adverse adverse event age assigned baseline Brazil C-reactive protein concentration cardiac disorder contribute Corticosteroids COVID-19 criteria CTCAE cytokine death demographics disease severity dose double-blind Efficacy and safety enrolled event GM-CSF granulocyte-macrophage colony-stimulating factor greater groups hazard ratio hospitalised hospitalised patient hyperinflammation Immune-mediated immunomodulator include Inflammatory intention-to-treat population intravenous dose Invasive mechanical ventilation investigated investigator IQR likelihood males median mITT mITT analysis modified intention-to-treat monoclonal antibody neutralising participant pathophysiology Patient patients with COVID-19 Phase 3 Placebo placebo-controlled trial Pneumonia primary endpoint Primary outcome randomisation randomised Randomly receive recruited Registered Remdesivir respiratory disorder Respiratory failure safety profile screened severity significantly standard supportive care steroid stratified study drug survival the placebo group treat treating COVID-19 treatment-emergent adverse event Trial USA were assessed with COVID-19
[DOI] 10.1016/S2213-2600(21)00494-X PMC 바로가기 [Article Type] Clinical Trial